The 5-year relative survival rate (i.e. rate compared with that of the age/gender/race-matched general population) for liver cancer is 20%. However, HCC is a very aggressive tumour, and the clinical course and survival depends upon the stage and overall functional status of the liver.[2]American Cancer Society. Cancer facts and figures. 2024 [internet publication].
https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2024-cancer-facts-figures.html
[136]Nanashima A, Omagari K, Tobinaga S, et al. Comparative study of survival of patients with hepatocellular carcinoma predicted by different staging systems using multivariate analysis. Eur J Surg Oncol. 2005 Oct;31(8):882-90.
http://www.ncbi.nlm.nih.gov/pubmed/15993031?tool=bestpractice.com
The 5-year survival for patients with symptomatic HCC is 0% to 10%.[137]Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003 Dec 6;362(9399):1907-17.
http://www.ncbi.nlm.nih.gov/pubmed/14667750?tool=bestpractice.com
Liver transplantation is the main course of therapy in patients with cirrhosis (including poor liver functional status), and post-transplant outcomes are very good with excellent long-term survival.[138]Santopaolo F, Lenci I, Milana M, et al. Liver transplantation for hepatocellular carcinoma: where do we stand? World J Gastroenterol. 2019 Jun 7;25(21):2591-602.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558441
http://www.ncbi.nlm.nih.gov/pubmed/31210712?tool=bestpractice.com
The 4-year survival rate after liver transplantation is 75%, with a tumour recurrence rate of 8% to 20%.[69]Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996 Mar 14;334(11):693-9.
https://www.nejm.org/doi/full/10.1056/NEJM199603143341104
http://www.ncbi.nlm.nih.gov/pubmed/8594428?tool=bestpractice.com
[138]Santopaolo F, Lenci I, Milana M, et al. Liver transplantation for hepatocellular carcinoma: where do we stand? World J Gastroenterol. 2019 Jun 7;25(21):2591-602.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558441
http://www.ncbi.nlm.nih.gov/pubmed/31210712?tool=bestpractice.com
Patients with well-compensated liver disease and good liver functional status may be candidates for surgical resection. The survival rates in non-cirrhotic patients treated with surgical resection are 58% at 3 years and 42% at 5 years.[75]Teh SH, Christein J, Donohue J, et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model of end-stage liver disease (MELD) score predicts perioperative mortality. J Gastrointest Surg. 2005 Dec;9(9):1207-15.
http://www.ncbi.nlm.nih.gov/pubmed/16332475?tool=bestpractice.com
Patients with intermediate-stage HCC treated with transarterial chemoembolisation (TACE) have a median overall survival of 19-20 months; some cohort studies have reported median survival of up to 40 months in well-selected patients with good TACE response.[139]Malagari K, Pomoni M, Moschouris H, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol. 2012 Oct;35(5):1119-28.
http://www.ncbi.nlm.nih.gov/pubmed/22614031?tool=bestpractice.com
[140]Takayasu K, Arii S, Kudo M, et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2012 Apr;56(4):886-92.
http://www.ncbi.nlm.nih.gov/pubmed/22173160?tool=bestpractice.com
Patients with advanced-stage HCC have been reported to have an overall median survival of 10.7 months.[112]Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90.
https://www.nejm.org/doi/full/10.1056/NEJMoa0708857
http://www.ncbi.nlm.nih.gov/pubmed/18650514?tool=bestpractice.com
Barcelona Clinic Liver Cancer (BCLC) staging
Overall, BCLC staging has the best prognostic assessment for survival compared with other staging systems.[72]Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022 Mar;76(3):681-93.
https://www.journal-of-hepatology.eu/article/S0168-8278(21)02223-6/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/34801630?tool=bestpractice.com
The expected median survival for patients with HCC is >5 years for BCLC stages 0 and A, >2.5 years for BCLC stage B, >2 years for BCLC stage C, and 3 months for BCLC stage D.[72]Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022 Mar;76(3):681-93.
https://www.journal-of-hepatology.eu/article/S0168-8278(21)02223-6/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/34801630?tool=bestpractice.com
For more information on the BCLC staging system, see Diagnostic criteria.
Cancer of the Liver Italian Programme (CLIP) staging
CLIP score of 0: survival is 31 months
CLIP score of 1: survival is 27 months
CLIP score of 2: survival is 13 months
CLIP score of 3: survival is 8 months
CLIP scores 4-6: survival is 2 months.
For more information on CLIP staging system see Diagnostic criteria.